FORA Capital’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

FORA Capital’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-956	Closed	-$44K	–	1382
2020 Q1	$44K	Buy	+956	New	+$48K	0.01%	793

Other funds holding EGRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

FORA Capital's EGRX Position: Q2 2020 in Review

FORA Capital sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2020, closing a stake of 956 shares — an estimated $44K sold.

FORA Capital first reported a position in EGRX in Q1 2020 and held it in 1 quarter. The position peaked at $44K in Q1 2020. 164 funds tracked by Wall St. Rank hold EGRX as of Q2 2020.

FORA Capital reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
FORA Capital sold 956 Eagle Pharmaceuticals, Inc. shares in Q2 2020, an estimated $44K.
FORA Capital first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2020 and held it in 1 quarter.
FORA Capital's Eagle Pharmaceuticals, Inc. position peaked at $44K in Q1 2020.
164 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2020.

Based on FORA Capital's 13F filing for Q2 2020, filed 14 Aug 2020.